Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Sell
37
NKTR Quote, Financials, Valuation and Earnings
Last price:
$0.86
Seasonality move
:
3.23%
Day range:
$0.82 - $0.92
52-week range:
$0.65 - $1.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.80x
P/B ratio:
2.64x
Volume:
1.6M
Avg. volume:
2.5M
1-year change:
-5.79%
Market cap:
$160.2M
Revenue:
$98.4M
EPS (TTM):
-$0.59
Analysts' Opinion
-
Consensus RatingNektar Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.75, Nektar Therapeutics has an estimated upside of 451.94% from its current price of $0.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.86.
Fair Value
-
According to the consensus of 5 analysts, Nektar Therapeutics has 451.94% upside to fair value with a price target of $4.75 per share.
NKTR vs. S&P 500
-
Over the past 5 trading days, Nektar Therapeutics has underperformed the S&P 500 by -6.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nektar Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nektar Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Nektar Therapeutics reported revenues of $29.2M.
Earnings Growth
-
Nektar Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nektar Therapeutics reported earnings per share of $0.03.
Enterprise value:
-95.1M
EV / Invested capital:
-1.57x
Price / LTM sales:
1.80x
EV / EBIT:
--
EV / Revenue:
-0.97x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$67.7M
Return On Assets:
-34.01%
Net Income Margin (TTM):
-120.86%
Return On Equity:
-133.07%
Return On Invested Capital:
-133.07%
Operating Margin:
-84.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $92.1M | $90.1M | $98.4M | $23.9M | $29.2M | |
| Gross Profit | $70.4M | $56.4M | $67.7M | $16.6M | $21.2M | |
| Operating Income | -$240.2M | -$135.2M | -$129.9M | -$30.7M | -$24.7M | |
| EBITDA | -$323M | -$243.1M | -$86.7M | -$33.6M | $17.5M | |
| Diluted EPS | -$1.97 | -$1.46 | -$0.59 | -$0.22 | $0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $795.6M | $546M | $330.7M | $261.3M | |
| Total Assets | $1.5B | $1.1B | $710.6M | $398M | $303.9M | |
| Current Liabilities | $115.8M | $85.2M | $68.2M | $51.3M | $61.4M | |
| Total Liabilities | $461.5M | $437.7M | $344M | $267M | $243.1M | |
| Total Equity | $1.1B | $679.5M | $366.6M | $131M | $60.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$304M | -$192.6M | -$175.7M | -$47M | -$46.2M | |
| Cash From Investing | $365.8M | $139.6M | $142.6M | $17.4M | $60.2M | |
| Cash From Financing | $1.5M | $30K | $42.1M | $12K | $83K | |
| Free Cash Flow | -$309.7M | -$193.5M | -$177.2M | -$47.3M | -$46.6M | |
NKTR
Sector
Market Cap
$160.2M
$39.2M
Price % of 52-Week High
44.64%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
1.74%
-0.81%
1-Year Price Total Return
-5.79%
-38.63%
Beta (5-Year)
0.649
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.87
200-day SMA
Sell
Level
$1.13
Bollinger Bands (100)
Sell
Level
0.81 - 1.17
Chaikin Money Flow
Sell
Level
-16.3M
20-day SMA
Sell
Level
$0.86
Relative Strength Index (RSI14)
Sell
Level
49.65
ADX Line
Buy
Level
13.13
Williams %R
Neutral
Level
-59.402
50-day SMA
Sell
Level
$0.87
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-106M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.0192)
Sell
CA Score
(Annual)
Level (-2.5671)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.3927)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Stock Forecast FAQ
In the current month, NKTR has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NKTR average analyst price target in the past 3 months is $4.75.
-
Where Will Nektar Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nektar Therapeutics share price will rise to $4.75 per share over the next 12 months.
-
What Do Analysts Say About Nektar Therapeutics?
Analysts are divided on their view about Nektar Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nektar Therapeutics is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Nektar Therapeutics's Price Target?
The price target for Nektar Therapeutics over the next 1-year time period is forecast to be $4.75 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NKTR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nektar Therapeutics is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NKTR?
You can purchase shares of Nektar Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nektar Therapeutics shares.
-
What Is The Nektar Therapeutics Share Price Today?
Nektar Therapeutics was last trading at $0.86 per share. This represents the most recent stock quote for Nektar Therapeutics. Yesterday, Nektar Therapeutics closed at $0.86 per share.
-
How To Buy Nektar Therapeutics Stock Online?
In order to purchase Nektar Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is down 28.36% over the past day.
Buy
58
TNXP alert for Mar 25
Tonix Pharmaceuticals Holding [TNXP] is up 32.39% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 17.3% over the past day.
